Skip to main content
Top
Gepubliceerd in: Quality of Life Research 5/2023

12-07-2022 | Special Section: Methodologies for Meaningful Change

Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata

Auteurs: Kathleen W. Wyrwich, Helen Kitchen, Sarah Knight, Natalie V. J. Aldhouse, Jake Macey, Natasha Mesinkovska, Justin M. Ko, Brett A. King

Gepubliceerd in: Quality of Life Research | Uitgave 5/2023

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

Traditionally, appropriate anchors are used to investigate the amount of change on a clinician-reported outcome assessment that is meaningful to individual patients. However, novel qualitative methods involving input from disease state experts together with patients may better inform the individual improvement threshold for demonstrating the clinical benefit of new treatments. This study aimed to establish a clinically meaningful threshold for treatment success for the clinician-reported Severity of Alopecia Tool (SALT) score for patients with alopecia areata (AA).

Methods

A purposive sample of 10 dermatologists expert in AA and 30 adult and adolescent patients with AA and a history of ≥ 50% scalp hair loss were recruited. Semi-structured interview questions explored the outcome that represented treatment success to clinicians and patients. Findings were analyzed using thematic methods to identify treatment success thresholds.

Results

Both informant groups confirmed scalp hair amount as the outcome of priority. Most expert clinicians considered a static threshold of 80% (n = 5) or 75% (n = 3) of the scalp hair as a treatment success. Most patient responses ranged from 70 to 90% (median: 80% of the scalp hair). Subsequently, queried patients confirmed that achieving SALT score ≤ 20 with treatment would be a success, as reflected in the Alopecia Areata Investigator Global Assessment (AA-IGA™). The novel qualitative processes used to inform this meaningful threshold reflects a clinician-then-patient process for: (a) confirmation of the patient outcome of priority; and (b) clinician input on a preliminary treatment success level for independent understanding among patients.

Conclusion

This qualitative investigation of expert clinicians-then-patients with AA confirmed that achieving an amount of 80% or more scalp hair (SALT score ≤ 20) was an appropriate individual treatment success threshold indicating clinically meaningful improvement for patients with ≥ 50% scalp hair loss. A qualitative investigation of a quantifiable treatment success threshold is possible through a well-designed interview process with expert clinicians and the appropriate patient population.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
go back to reference Liu, L. Y., King, B. A., & Craiglow, B. G. (2016). Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal of the American Academy of Dermatology, 75(4), 806–12.e3.CrossRefPubMed Liu, L. Y., King, B. A., & Craiglow, B. G. (2016). Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review. Journal of the American Academy of Dermatology, 75(4), 806–12.e3.CrossRefPubMed
2.
go back to reference Rencz, F., Gulácsi, L., Péntek, M., Wikonkál, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed Rencz, F., Gulácsi, L., Péntek, M., Wikonkál, N., Baji, P., & Brodszky, V. (2016). Alopecia areata and health-related quality of life: A systematic review and meta-analysis. British Journal of Dermatology, 175(3), 561–571.CrossRefPubMed
3.
go back to reference Davis, D. S., & Callender, V. D. (2018). Review of quality of life studies in women with alopecia. International Journal of Women’s Dermatology, 4(1), 18–22.CrossRefPubMedPubMedCentral Davis, D. S., & Callender, V. D. (2018). Review of quality of life studies in women with alopecia. International Journal of Women’s Dermatology, 4(1), 18–22.CrossRefPubMedPubMedCentral
4.
go back to reference Wolf, J. J., & Hudson, B. P. (2019). Alopecia areata: Factors that impact children and adolescents. Journal of Adolescent Research., 34(3), 282–301.CrossRef Wolf, J. J., & Hudson, B. P. (2019). Alopecia areata: Factors that impact children and adolescents. Journal of Adolescent Research., 34(3), 282–301.CrossRef
5.
go back to reference Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: An online qualitative survey study. British Journal of Dermatology., 180(6), 1377–1389.CrossRefPubMed Davey, L., Clarke, V., & Jenkinson, E. (2019). Living with alopecia areata: An online qualitative survey study. British Journal of Dermatology., 180(6), 1377–1389.CrossRefPubMed
6.
go back to reference Aldhouse, N. V. J., Kitchen, H., Knight, S., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., King, B. A., & Wyrwich, K. W. (2020). “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” A qualitative interview study to understand the psychosocial burden of alopecia areata. Journal of Patient-Reported Outcomes, 4(1), 76.CrossRefPubMedPubMedCentral Aldhouse, N. V. J., Kitchen, H., Knight, S., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., King, B. A., & Wyrwich, K. W. (2020). “‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” A qualitative interview study to understand the psychosocial burden of alopecia areata. Journal of Patient-Reported Outcomes, 4(1), 76.CrossRefPubMedPubMedCentral
7.
go back to reference Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., Jr., McMichael, A. J., Randall, V. A., Turner, M. L., Sperling, L., Whiting, D. A., Norris, D., National Alopecia Areata Foundation. (2004). Alopecia areata investigational assessment guidelines—Part II. National Alopecia Areata Foundation. Journal of the American Academy of Dermatology, 51(3), 440–447.CrossRefPubMed Olsen, E. A., Hordinsky, M. K., Price, V. H., Roberts, J. L., Shapiro, J., Canfield, D., Duvic, M., King, L. E., Jr., McMichael, A. J., Randall, V. A., Turner, M. L., Sperling, L., Whiting, D. A., Norris, D., National Alopecia Areata Foundation. (2004). Alopecia areata investigational assessment guidelines—Part II. National Alopecia Areata Foundation. Journal of the American Academy of Dermatology, 51(3), 440–447.CrossRefPubMed
8.
go back to reference Wambier, C. G., & King, B. A. (2019). Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal of the American Academy of Dermatology, 81(2), 630–631.CrossRefPubMed Wambier, C. G., & King, B. A. (2019). Rule of thumb: A simple tool to estimate 1% scalp surface area. Journal of the American Academy of Dermatology, 81(2), 630–631.CrossRefPubMed
9.
go back to reference Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 1(15), e89790.CrossRefPubMedPubMedCentral Mackay-Wiggan, J., Jabbari, A., Nguyen, N., Cerise, J. E., Clark, C., Ulerio, G., Furniss, M., Vaughan, R., Christiano, A. M., & Clynes, R. (2016). Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight, 1(15), e89790.CrossRefPubMedPubMedCentral
10.
go back to reference Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C., Marinkovich, M. P., Christiano, A. M., Oro, A. E., & King, B. A. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15), e89776.CrossRefPubMedPubMedCentral Kennedy Crispin, M., Ko, J. M., Craiglow, B. G., Li, S., Shankar, G., Urban, J. R., Chen, J. C., Cerise, J. E., Jabbari, A., Winge, M. C., Marinkovich, M. P., Christiano, A. M., Oro, A. E., & King, B. A. (2016). Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight, 1(15), e89776.CrossRefPubMedPubMedCentral
11.
go back to reference FDA. (2018). Discussion document for the patient-focused drug development public workshop on guidance 3: Select, develop or modify fit-for-purpose clinical outcome assessments. Prepared for a patient-focused drug development guidance public workshop held on October 15–16, 2018. https://www.fda.gov/media/116277/download FDA. (2018). Discussion document for the patient-focused drug development public workshop on guidance 3: Select, develop or modify fit-for-purpose clinical outcome assessments. Prepared for a patient-focused drug development guidance public workshop held on October 15–16, 2018. https://​www.​fda.​gov/​media/​116277/​download
12.
go back to reference McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011). Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 163–169.CrossRef McLeod, L. D., Coon, C. D., Martin, S. A., Fehnel, S. E., & Hays, R. D. (2011). Interpreting patient-reported outcome results: US FDA guidance and emerging methods. Expert Review of Pharmacoeconomics & Outcomes Research, 11(2), 163–169.CrossRef
13.
go back to reference Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22(3), 475–483.CrossRefPubMed Wyrwich, K. W., Norquist, J. M., Lenderking, W. R., & Acaster, S. (2013). Methods for interpreting change over time in patient-reported outcome measures. Quality of Life Research, 22(3), 475–483.CrossRefPubMed
14.
go back to reference Coon, C. D., & Cappelleri, J. C. (2016). Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci., 50(1), 22–29.CrossRefPubMed Coon, C. D., & Cappelleri, J. C. (2016). Interpreting change in scores on patient-reported outcome instruments. Ther Innov Regul Sci., 50(1), 22–29.CrossRefPubMed
15.
go back to reference Guidance for industry. (2006). patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes, 11(4), 79. Guidance for industry. (2006). patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health and Quality of Life Outcomes, 11(4), 79.
16.
go back to reference Gelhorn, H. L., Kulke, M. H., O’Dorisio, T., Yang, Q. M., Jackson, J., Jackson, S., Boehm, K. A., Law, L., Kostelec, J., Auguste, P., & Lapuerta, P. (2016). Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach. Clinical Therapeutics, 38(4), 759–768.CrossRefPubMedPubMedCentral Gelhorn, H. L., Kulke, M. H., O’Dorisio, T., Yang, Q. M., Jackson, J., Jackson, S., Boehm, K. A., Law, L., Kostelec, J., Auguste, P., & Lapuerta, P. (2016). Patient-reported symptom experiences in patients with carcinoid syndrome after participation in a study of telotristat etiprate: A qualitative interview approach. Clinical Therapeutics, 38(4), 759–768.CrossRefPubMedPubMedCentral
17.
go back to reference Peay, H., Kennedy, A., Fischer, R., Bronson, A., & Furlong, P. (2016). Promoting meaningful clinical trial outcome measures for Duchenne muscular dystrophy. Neuromuscular Disorders., 26, S187.CrossRef Peay, H., Kennedy, A., Fischer, R., Bronson, A., & Furlong, P. (2016). Promoting meaningful clinical trial outcome measures for Duchenne muscular dystrophy. Neuromuscular Disorders., 26, S187.CrossRef
18.
go back to reference McGraw, S., Qian, Y., Henne, J., Jarecki, J., Hobby, K., & Yeh, W. S. (2017). A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurology, 17(1), 68.CrossRefPubMedPubMedCentral McGraw, S., Qian, Y., Henne, J., Jarecki, J., Hobby, K., & Yeh, W. S. (2017). A qualitative study of perceptions of meaningful change in spinal muscular atrophy. BMC Neurology, 17(1), 68.CrossRefPubMedPubMedCentral
19.
go back to reference Arbuckle, R., Staunton, H., Sully, K., Tomkins, S., Khindri, S., Svedsater, H., & Nelsen, L. (2019). Use of both qualitative and quantitative methods to estimate meaningful change thresholds for key endpoints in pediatric asthma trials. Value in Health, 22(3), 340–347.CrossRefPubMed Arbuckle, R., Staunton, H., Sully, K., Tomkins, S., Khindri, S., Svedsater, H., & Nelsen, L. (2019). Use of both qualitative and quantitative methods to estimate meaningful change thresholds for key endpoints in pediatric asthma trials. Value in Health, 22(3), 340–347.CrossRefPubMed
20.
go back to reference Kitchen, H., Seitz, C., Trigg, A., Aldhouse, N., Willgoss, T., Schmitz, H., Gater, A., Gerlinger, C., & Haberland, C. (2021). Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Health and Quality of Life Outcomes, 19(1), 7.CrossRefPubMedPubMedCentral Kitchen, H., Seitz, C., Trigg, A., Aldhouse, N., Willgoss, T., Schmitz, H., Gater, A., Gerlinger, C., & Haberland, C. (2021). Patients’ and clinicians’ perspectives on item importance, scoring, and clinically meaningful differences for the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS). Health and Quality of Life Outcomes, 19(1), 7.CrossRefPubMedPubMedCentral
21.
go back to reference Staunton, H., Willgoss, T., Nelsen, L., Burbridge, C., Sully, K., Rofail, D., & Arbuckle, R. (2019). An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. Journal of Patient-Reported Outcomes, 3(1), 16.CrossRefPubMedPubMedCentral Staunton, H., Willgoss, T., Nelsen, L., Burbridge, C., Sully, K., Rofail, D., & Arbuckle, R. (2019). An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. Journal of Patient-Reported Outcomes, 3(1), 16.CrossRefPubMedPubMedCentral
22.
go back to reference Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology., 3(2), 77–101.CrossRef Braun, V., & Clarke, V. (2006). Using thematic analysis in psychology. Qualitative Research in Psychology., 3(2), 77–101.CrossRef
23.
go back to reference Guest, G., MacQueen, K. M., & Namey, E. E. (2011). Applied thematic analysis. Sage. Guest, G., MacQueen, K. M., & Namey, E. E. (2011). Applied thematic analysis. Sage.
24.
go back to reference Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) Measures for eyebrow, eyelash and nail assessment in alopecia areata. American Journal of Clinical Dermatology, 21(5), 725–732.CrossRefPubMedPubMedCentral Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) Measures for eyebrow, eyelash and nail assessment in alopecia areata. American Journal of Clinical Dermatology, 21(5), 725–732.CrossRefPubMedPubMedCentral
25.
go back to reference Friese S. ATLAS.ti 7 User Manual Copyright ©2014 by ATLAS.ti Scientific Software Development GmbH, Berlin. All rights reserved. Manual Version: 190.20140902. Updated for program version: 7.5 2014 Contract No.: Document Number|. Friese S. ATLAS.ti 7 User Manual Copyright ©2014 by ATLAS.ti Scientific Software Development GmbH, Berlin. All rights reserved. Manual Version: 190.20140902. Updated for program version: 7.5 2014 Contract No.: Document Number|.
26.
go back to reference Langley, R. G., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015). The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. The Journal of Dermatological Treatment, 26(1), 23–31.CrossRefPubMed Langley, R. G., Feldman, S. R., Nyirady, J., van de Kerkhof, P., & Papavassilis, C. (2015). The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. The Journal of Dermatological Treatment, 26(1), 23–31.CrossRefPubMed
27.
go back to reference Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). The Alopecia Areata Investigator Global Assessment scale: A measure for evaluating clinically meaningful success in clinical trials. British Journal of Dermatology, 183(4), 702–709.CrossRefPubMed Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). The Alopecia Areata Investigator Global Assessment scale: A measure for evaluating clinically meaningful success in clinical trials. British Journal of Dermatology, 183(4), 702–709.CrossRefPubMed
28.
go back to reference Olsen, E. A. (2011). Investigative guidelines for alopecia areata. Dermatologic Therapy, 24(3), 311–319.CrossRefPubMed Olsen, E. A. (2011). Investigative guidelines for alopecia areata. Dermatologic Therapy, 24(3), 311–319.CrossRefPubMed
29.
go back to reference Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F., Dutronc, Y., Mesinkovska, N. A., Ko, J. M., & King, B. A. (2020). The role of patients in alopecia areata endpoint development: understanding physical signs and symptoms. The Journal of Investigative Dermatology Symposium Proceedings, 20(1), S71–S77.CrossRefPubMed Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F., Dutronc, Y., Mesinkovska, N. A., Ko, J. M., & King, B. A. (2020). The role of patients in alopecia areata endpoint development: understanding physical signs and symptoms. The Journal of Investigative Dermatology Symposium Proceedings, 20(1), S71–S77.CrossRefPubMed
30.
go back to reference Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal of Dermatology, 183(6), 1065–1072.CrossRefPubMed Wyrwich, K. W., Kitchen, H., Knight, S., Aldhouse, N. V. J., Macey, J., Nunes, F. P., Dutronc, Y., Mesinkovska, N., Ko, J. M., & King, B. A. (2020). Development of the Scalp Hair Assessment PRO™ measure for alopecia areata. British Journal of Dermatology, 183(6), 1065–1072.CrossRefPubMed
31.
go back to reference Macey, J., Kitchen, H., Aldhouse, N. V. J., Burge, R. T., Edson-Heredia, E., McCollam, J. S., Isaka, Y., & Torisu-Itakura, H. (2021). Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in Japan. Dermatol Ther (Heidelb), 11(2), 433–447.CrossRefPubMedPubMedCentral Macey, J., Kitchen, H., Aldhouse, N. V. J., Burge, R. T., Edson-Heredia, E., McCollam, J. S., Isaka, Y., & Torisu-Itakura, H. (2021). Dermatologist and patient perceptions of treatment success in alopecia areata and evaluation of clinical outcome assessments in Japan. Dermatol Ther (Heidelb), 11(2), 433–447.CrossRefPubMedPubMedCentral
32.
go back to reference Chalasani, M., Vaidya, P., & Mullin, T. (2018). Enhancing the incorporation of the patient’s voice in drug development and evaluation. Research Involvement and Engagement, 4, 10.CrossRefPubMedPubMedCentral Chalasani, M., Vaidya, P., & Mullin, T. (2018). Enhancing the incorporation of the patient’s voice in drug development and evaluation. Research Involvement and Engagement, 4, 10.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata
Auteurs
Kathleen W. Wyrwich
Helen Kitchen
Sarah Knight
Natalie V. J. Aldhouse
Jake Macey
Natasha Mesinkovska
Justin M. Ko
Brett A. King
Publicatiedatum
12-07-2022
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 5/2023
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-022-03170-7

Andere artikelen Uitgave 5/2023

Quality of Life Research 5/2023 Naar de uitgave

Special Section: Methodologies for Meaningful Change

Measuring individual true change with PROMIS using IRT-based plausible values